Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | GAA | P10253 | 2/20 | 0.74 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.67 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.67 |
| ▸ | CDK2 | P24941 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4216370 | 0.90 | MAPT (0.79) | MAPTKMT2AMEN1GAAPLA2G1B | |
| SCHEMBL4217682 | 0.89 | MAPT (0.77) | MAPTKMT2AMEN1GAAPLA2G1B | |
| SCHEMBL14280728 | 0.88 | MAPT (0.76) | MAPTKMT2AMEN1GAAPLA2G1B | |
| SCHEMBL13802486 | 0.86 | MAPT (0.56) | MAPTKMT2AMEN1GAAPLA2G1B | |
| SCHEMBL14280729 | 0.85 | CDK2 (0.77) | MAPTKMT2AMEN1GAAPLA2G1B | |
| SCHEMBL4212246 | 0.85 | MAPT (1.00) | MAPTKMT2AMEN1GAAPLA2G1B | |
| SCHEMBL4211567 | 0.85 | MAPT (0.71) | MAPTKMT2AMEN1GAAPLA2G1B | |
| SCHEMBL4209793 | 0.85 | MAPT (0.74) | MAPTKMT2AMEN1GAAPLA2G1B | |
| SCHEMBL4207992 | 0.85 | MAPT (0.74) | MAPTKMT2AMEN1GAAPLA2G1B | |
| SCHEMBL4201585 | 0.83 | MAPT (0.85) | MAPTKMT2AMEN1GAAPLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20080021085-A1 | METHOD OF REDUCING ABETA42 AND TREATING DISEASES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | MAPT 6/4885KMT2A 2408/4885MEN1 694/4885 |
| US-20080021085-A1 | METHOD OF REDUCING ABETA42 AND TREATING DISEASES | BACE1, BACE2, APP | MAPT 80/4885KMT2A 1301/4885MEN1 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.